Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Kowa Company, Ltd. Snapshot | 6 | 1 |
| Kowa Company, Ltd. Overview | 6 | 1 |
| Key Information | 6 | 1 |
| Key Facts | 6 | 1 |
| Kowa Company, Ltd. Research and Development Overview | 7 | 3 |
| Key Therapeutic Areas | 7 | 3 |
| Kowa Company, Ltd. Pipeline Review | 10 | 4 |
| Pipeline Products by Stage of Development | 10 | 1 |
| Pipeline Products Monotherapy | 11 | 1 |
| Pipeline Products Partnered Products | 12 | 1 |
| Partnered Products/Combination Treatment Modalities | 13 | 1 |
| Kowa Company, Ltd. Pipeline Products Glance | 14 | 7 |
| Kowa Company, Ltd. Late Stage Pipeline Products | 14 | 1 |
| Pre-Registration Products/Combination Treatment Modalities | 14 | 1 |
| Phase III Products/Combination Treatment Modalities | 15 | 1 |
| Kowa Company, Ltd. Clinical Stage Pipeline Products | 16 | 1 |
| Phase II Products/Combination Treatment Modalities | 16 | 1 |
| Phase I Products/Combination Treatment Modalities | 17 | 1 |
| Kowa Company, Ltd. Early Stage Pipeline Products | 18 | 1 |
| Preclinical Products/Combination Treatment Modalities | 18 | 1 |
| Discovery Products/Combination Treatment Modalities | 19 | 1 |
| Kowa Company, Ltd. - Unknown Stage Pipeline Products | 20 | 1 |
| Unknown Products/Combination Treatment Modalities | 20 | 1 |
| Kowa Company, Ltd. Drug Profiles | 21 | 17 |
| pemafibrate | 21 | 1 |
| Product Description | 21 | 1 |
| Mechanism of Action | 21 | 1 |
| R&D Progress | 21 | 3 |
| anagliptin | 24 | 1 |
| Product Description | 24 | 1 |
| Mechanism of Action | 24 | 1 |
| R&D Progress | 24 | 2 |
| peretinoin | 26 | 1 |
| Product Description | 26 | 1 |
| Mechanism of Action | 26 | 1 |
| R&D Progress | 26 | 2 |
| K-134 | 28 | 1 |
| Product Description | 28 | 1 |
| Mechanism of Action | 28 | 1 |
| R&D Progress | 28 | 1 |
| ripasudil | 29 | 1 |
| Product Description | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| R&D Progress | 29 | 2 |
| epirubicin hydrochloride | 31 | 1 |
| Product Description | 31 | 1 |
| Mechanism of Action | 31 | 1 |
| R&D Progress | 31 | 1 |
| K-312 | 32 | 1 |
| Product Description | 32 | 1 |
| Mechanism of Action | 32 | 1 |
| R&D Progress | 32 | 1 |
| pitavastatin NP | 33 | 1 |
| Product Description | 33 | 1 |
| Mechanism of Action | 33 | 1 |
| R&D Progress | 33 | 1 |
| Small Molecule to Agonize LXRB for Atherosclerosis | 34 | 1 |
| Product Description | 34 | 1 |
| Mechanism of Action | 34 | 1 |
| R&D Progress | 34 | 1 |
| Small Molecule to Inhibit Acyl-Coenzyme A for Undisclosed Indication | 35 | 1 |
| Product Description | 35 | 1 |
| Mechanism of Action | 35 | 1 |
| R&D Progress | 35 | 1 |
| Small Molecule for Oncology | 36 | 1 |
| Product Description | 36 | 1 |
| Mechanism of Action | 36 | 1 |
| R&D Progress | 36 | 1 |
| K-163SZ | 37 | 1 |
| Product Description | 37 | 1 |
| Mechanism of Action | 37 | 1 |
| R&D Progress | 37 | 1 |
| Kowa Company, Ltd. Pipeline Analysis | 38 | 6 |
| Kowa Company, Ltd. Pipeline Products by Target | 38 | 2 |
| Kowa Company, Ltd. Pipeline Products by Route of Administration | 40 | 1 |
| Kowa Company, Ltd. Pipeline Products by Molecule Type | 41 | 1 |
| Kowa Company, Ltd. Pipeline Products by Mechanism of Action | 42 | 2 |
| Kowa Company, Ltd. Recent Pipeline Updates | 44 | 3 |
| Kowa Company, Ltd. Dormant Projects | 47 | 1 |
| Kowa Company, Ltd. - Discontinued Pipeline Products | 48 | 1 |
| Discontinued Pipeline Product Profiles | 48 | 1 |
| pitavastatin CR | 48 | 1 |
| Kowa Company, Ltd. Locations And Subsidiaries | 49 | 3 |
| Head Office | 49 | 1 |
| Other Locations &Subsidiaries | 49 | 3 |
| Appendix | 52 | 2 |
| Methodology | 52 | 1 |
| Coverage | 52 | 1 |
| Secondary Research | 52 | 1 |
| Primary Research | 52 | 1 |
| Expert Panel Validation | 52 | 1 |
| Contact Us | 52 | 1 |
| Disclaimer | 53 | 1 |